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Abstract 
Background: Subretinal cell transplantation is a challenging surgical maneuver. This paper describes the preliminary 
findings of a new tissue injector for subretinal implantation of an ultrathin non‑absorbable substrate seeded with 
human embryonic stem cell‑derived retinal pigment epithelium (hESC‑RPE).
Methods: Ultrathin Parylene‑C substrates measuring 3.5 mm × 6.0 mm seeded with hESC‑RPE (implant referred to 
as CPCB‑RPE1) were implanted into the subretinal space of 12 Yucatan minipigs. Animals were euthanized immedi‑
ately after the procedure and underwent spectral domain optical coherence tomography (SD‑OCT) and histological 
analysis to assess the subretinal placement of the implant. Evaluation of the hESC‑RPE cells seeded on the substrate 
was carried out before and after implantation using standard cell counting techniques.
Results: The tissue injector delivered the CPCB‑RPE1 implant through a 1.5 mm sclerotomy and a 1.0–1.5 mm reti‑
nectomy. SD‑OCT scans and histological examination revealed that substrates were precisely placed in the subreti‑
nal space, and that the hESC‑RPE cell monolayer continued to cover the surface of the substrate after the surgical 
procedure.
Conclusion: This innovative tissue injector was able to efficiently deliver the implant in the subretinal space of 
Yucatan minipigs, preventing significant hESC‑RPE cell loss, minimizing tissue trauma, surgical complications and 
postoperative inflammation.
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Background
Age-related macular degeneration (AMD) is the lead-
ing cause of severe visual loss and legal blindness in the 
elderly population [1, 2]. Although anti-angiogenic ther-
apies have been developed to treat exudative AMD [3], 
there is no effective treatment for dry AMD, specially at 
its end stage, namely, geographic atrophy [4, 5]. Previous 
studies have demonstrated that dysfunction and/or death 
of retinal pigment epithelium (RPE) cells play a critical 
role in the pathophysiology of dry AMD and that RPE 
transplantation has the potential to halt further degen-
eration and restore visual function [6, 7].
Stem cells have the capacity to differentiate and replace 
damaged cells, providing an unlimited source of RPE cells 
for transplantation purposes [8]. In normal retinas, RPE 
cells consist of a polarized monolayer and embryonic 
stem cell-derived retinal pigment epithelium (hESC-RPE) 
cells cultured on an ultrathin substrate (e.g. Parylene-C) 
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have similar characteristics. Although ultrathin sub-
strates are theoretically good scaffolds for subretinal 
transplantation due to their permeability, they are usu-
ally soft and malleable. Their implantation often requires 
challenging surgical maneuvers, resulting in a large reti-
nectomy associated with damage to the surrounding 
tissue.
The present study demonstrates a new tissue injector 
designed to perform subretinal transplantation of Par-
ylene-C substrates seeded with hESC-RPE cells (implant 
referred to as CPCB-RPE1) in a safe and reproducible 
procedure, leading to minimal damage to the host retina 
as well as preventing significant hESC-RPE cell loss dur-
ing the implantation.
Methods
Mesh membrane
A mesh-supported sub-micron Parylene-C membrane 
(MSPM) is a class VI material (i.e. implant grade) com-
prised of a 0.30  μm thick Parylene-C membrane and a 
6.0  μm thick supporting mesh (Fig.  1). The MSPM sur-
face was seeded with hESC-RPE cells and treated with 
oxygen plasma. Parylene-C was provided by Specialty 
Coating Systems (Indianapolis, IN, USA), while the 
MSPM was provided by the California Institute of Tech-
nology (Los Angeles, CA, USA). Sub-micron Parylene-C 
is ultrathin, and its molecular weight, exclusion limit, and 
permeability are similar to the Bruch’s membrane [9–11] 
and, therefore, it is considered a good candidate for its 
replacement. Additionally, Parylene-C demonstrates low 
potential harmful effects in the subretinal environment 
[12].
This configuration allows for the formation of a polar-
ized, confluent, functional monolayer of RPE cells, 
provides the mechanical support required for surgi-
cal implantation, and promotes the reciprocal exchange 
of nutrients and waste products between the RPE and 
choroid.
Cell culture for implants
Human embryonic stem cells (Wicell, Madison, WI, 
USA) were spontaneously differentiated into RPE cells 
as described previously [11]. These hESC-RPE cells were 
cultured and maintained in serum-free medium X-VIVO 
10 Lonza (Walkersville, Maryland, MD, USA) on Syn-
themax plates (Corning, New York, NY, USA). Based on 
staining with RPE markers, cultures showed over 95% of 
purity [13].
In the second passage, hESC-RPE cells were dissoci-
ated with trypsin (TrypLE—Invitrogen, Carlsbad, CA, 
USA) and seeded on MSPM films (3.5  mm  ×  6  mm) 
coated with vitronectin (BD Biosciences Franklin Lakes, 
NJ, USA) at a cell density of  105/cm2. Cells were main-
tained in culture on the ultrathin parylene substrates for 
4 weeks with the medium changed twice weekly.
Fig. 1 A 3.5 × 6 mm implant with 2 mm handle. a Unseeded. b Seeded with hESC‑RPE
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A post mortem study showed a mean density of 
approximately 5000 RPE cells/mm2 on the macular area 
[14]. Based on the dimensions of the scaffolds, and the 
mean density of cells on the substrate (6200  RPE cells/
mm2) individual CPCB-RPE1 implants had approxi-
mately a total of 125,000 cells. (Fig.  1).
Tissue injector
A first set of surgeries was performed in Yucatan mini-
pigs using a 15-gauge prototype tissue injector to deliver 
hESC-RPE monolayer seeded over 4.5 mm × 4.5 mm Par-
ylene-C substrates into their subretinal space (unpublished 
data). Based on this preliminary experience, the size of 
the substrate was reduced to 3.5 mm × 6 mm in order to 
decrease the diameter of the surgical injector and, conse-
quently, the required sclerotomy and retinectomy (Fig. 2). 
The reduction in the size of the implant is consistent with 
the size of the macular area in order to maintain the same 
functionality. A new tissue injector prototype of 17-gauge 
was developed to handle this smaller substrate (Fig. 3).
The two versions of the tissue injector tools are shown 
in Figs. 4 and 5 with dimensions referenced for the major 
components of the injector. Dimensions are given for the 
extended and retracted positions to store and protect the 
membrane during insertion and deliver the substrate to 
the eye respectively.
Fig. 2 Comparison between the 15 gauge a versus 17 gauge b tissue injector. Tip design improvement prevent implant damage
Fig. 3 Injector design: previous version (a) versus latest version (b)
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Version 1 of the tissue insertion consisted of an over-
all length of 175.8  mm when retracted and 183.3  mm 
when extended. The tool length was driven by the pri-
mary need to store the forceps and substrate completely 
during retraction and a secondary need to remain short 
enough that it would not impede ergonomics of the sur-
geon during use. During the iteration between the two 
versions, both the overall membrane length and forceps 
length were shortened, allowing the length of the tube at 
the front and the tool’s body to be shortened by 3.5 mm. 
Fig. 4 Tissue injector, version one shown in the extended and retracted position. The diameter of the tool measures 11.4 mm at the largest cross 
section and has an overall length of 175.8 mm when retracted (b) and 183.3 mm when fully extended (a). The tube measures 1.59 mm ID × 1.83 
mm OD and has a length of 36.1 mm as measured from the tip of the tool’s body
Fig. 5 Tissue injector, version two shown in the extended and retracted position. The diameter of the tool measures 17.8 mm at the largest 
cross section and has an overall length of 152.0 mm when retracted (b) and 158.6 mm when fully extended (a). The tube measures 1.27 mm 
ID × 1.47 mm OD and has a length of 32.6 mm as measured from the tip of the tool’s body
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The new mechanism and the reduced length of the tube 
then allowed the body to also be shortened an addi-
tional 20.3  mm. Leading to an overall length reduction 
of 23.8 mm between versions with a retracted length of 
152.0 mm and extended length of 158.6 mm.
The diameter of the tools at the largest cross section 
was increased between version iterations from 11.4 mm 
at the largest cross section in version one, up to a diam-
eter of 17.8 mm in version two. The increased diameter 
between versions of the tool was driven by both the 
larger size of the internal mechanism and user feedback 
during experiments that a larger diameter would be more 
ergonomic for handling during procedures.
The internal lumen circumference must correspond 
to the width of the MSPM in order to fold the substrate 
without overlapping its edges inside of the instrument. 
Any overlap of the substrate edges could lead to loss of 
cells from the substrate.
The CPCB-RPE1 implant consisted of a rectangu-
lar portion with rounded edges intended to support the 
seeded hESC-RPE cells, and a 2 mm handle to allow its 
manipulation with a standard intraocular forceps and the 
tissue injector. A round marker on the side of the han-
dle was added to identify which side was seeded with 
cells (marker always facing right during seeding and 
implantation).
Surgical technique
In order to verify the safety and reproducibility of the 
surgical procedure for future application in human eyes, 
we have assessed the surgical tools, as well as the surgi-
cal techniques to deliver the implant into the subretinal 
space of 12 Yucatan minipigs. This animal model was 
chosen because the size and shape of the eye are very 
similar to human eyes, and previous studies showed that 
subretinal implantation in this model was a feasible pro-
cedure [12].
All experiments were performed in compliance with 
the ARVO statement of the use of Animals in Ophthal-
mic and Vision Research under a protocol approved by 
the Animal Care and Use Committee (IACUC) at the 
University of Southern California.
The surgical technique of implantation of the MPSM 
seeded with hESC-RPE consisted of Pars Plana Vitrec-
tomy (PPV), a 1  mm retinectomy anterior to the equa-
tor followed by the placement of the substrate seeded 
with cells under the retina using the novel tissue injector 
(Fig. 6).
Pigs were submitted to general anesthesia using 
Xylazine/Telazol 1.1–2.2  mg/kg; Glycopyrrolate 
0.01–0.04  mg/kg; SEVOfluarane/Isoflurane 1.0–3.5%; 
Buprenorphine 0.05–0.1  mg/kg; Rimadyl 2–4  mg/kg, 
conducted by a trained veterinary staff under veterinary 
supervision. The left eye was dilated using 1% tropi-
camide and phenylephrine eye drops. Proper asepsis with 
povidone iodine 10% was applied to the area surround-
ing the eye and the entire surgical field using 1% betadine 
drops instilled on the eye.
The eye was draped in a sterile surgical field and an 
eyelid speculum was applied. Lateral canthotomies and 
proper hemostasis were performed temporally to facili-
tate surgical manipulation. Three 25-gauge trocars were 
placed at 3.5 mm from the limbus as well as two 29-gauge 
chandeliers (Synergetics TM, USA), connected to the 
Photon 2 illumination system were used (Synergetics 
TM, USA).
Pars plana vitrectomy (PPV) was performed by a 
core vitrectomy using 600  mmHg vacuum, 5000  cuts/
min, using the Stellaris PC Surgical system (Bausch and 
Lomb, USA), and a 25 gauge vitrectomy probe (Bausch 
and Lomb, USA). The Zeiss Opmi Microscope (Zeiss, 
Germany) was used with the Oculus Binocular Indi-
rect Ophthalmic Microscope wide-angle visual system 
(BIOM System, USA). Staining of the posterior hyaloid 
was performed using 0.3  ml of triamcinolone aceton-
ide  (Triesence® 40 mg/ml, Alcon, Inc., Fort Worth, TX, 
USA) followed by posterior hyaloid detachment using 
an aspiration rate of 200  mmHg until no residual vitre-
ous (shown by triamcinolone) was observed at the retinal 
surface.
A complete vitrectomy was performed including 360° 
vitreous base shaving, followed by inspection of the vitre-
ous base in order to rule out retinal tears.
After vitreous shaving, the posterior pole and supe-
rior retina was detached using a 41-gauge needle injec-
tion (Bausch and Lomb, USA) of approximately 1 ml of 
balanced saline solution (BSS) starting near the optic 
nerve head, creating a retinal bleb. Endodiathermy was 
performed anterior to the equator outside of the vas-
cular arcades, comprising 1  mm, in a linear fashion, 
followed by retinectomy performed with the vitrec-
tomy probe. A superior nasal sclerotomy was enlarged 
to 1.5  mm, allowing the tissue injector to place the 
seeded substrate under the retina, close to the optic 
nerve (Fig. 6).
Perfluorocarbon liquid (PFO) was slowly injected on 
the retinal surface to reattach the retina—filling the entire 
posterior pole—until subretinal fluid was completely dis-
placed from the subretinal space. The 1.5 mm temporal 
sclerotomy was sutured using Vicryl 6.0. Endophotoco-
agulation was performed on the edges of the retinectomy, 
with at least three rows, followed by fluid-air exchange, 
and then the eye was filled with silicone oil 1000 cen-
tistokes Oxane™ (Bausch and Lomb, USA). Finally, the 
eye was patched with ointment containing corticoster-
oids and antibiotics.
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The lens and anterior segment remained untouched 
during the procedure in order to prevent media opacities.
All study animals were euthanized immediately after 
the surgical procedure and imaging with 0.5  ml of 
pentobarbitol sodium 390  mg and phenytoin sodium 
50  mg (Euthasol, Virbac AH, Inc, Forth Worth, TX, 
USA).
Post‑operative analysis
The implanted animals were evaluated before and imme-
diately after the surgical procedure with the Heidel-
berg Spectralis™ SD-OCT (Heidelberg Engineering, 
Germany).
The imaging protocol was comprised of volume scans 
performed with SD-OCT, fluorescein angiogram (FA), 
fundus autofluorescence (FAF), color fundus photo-
graphs and Infrared (IR) images.
Color fundus photographs were taken of both eyes. IR 
images, FAF and FA were taken within 3 min of acquir-
ing time (Heidelberg Spectralis, HRA-OCT) in both 
eyes. SD-OCT images (Heidelberg Spectralis-HRA) were 
also taken for both eyes using the following protocol: (1) 
High definition scans through the optic nerve; (2) volume 
scans (30 × 30) centered on the optic nerve; (3) volume 
scans (30  ×  30) of the temporal retina with the optic 
nerve on the edge of the scan; (4) nerve fiber layer scans 
centered on the optic nerve.
Histological evaluation and immunohistochemistry
After implantation, animals were euthanized and the 
enucleated eyes were fixed in Davidson’s solution for 
24  h. For light microscopy, the tissue was stained with 
Hematoxylin and Eosin (HE) and evaluated using 
the M500 microscope (Leica, Wetzlar, Germany). 
Fig. 6 a Anterior segment and lens status during and after the surgical procedure. b Injector forceps holding the substrate by the handle. c Injector 
folding the substrate. d Injection of saline in the subretinal space. e Subretinal unfolding and placement. f Posterior pole aspect at the end of the 
surgical procedure
Page 7 of 9Fernandes et al. Int J Retin Vitr  (2017) 3:41 
Immunohistochemistry analysis was performed with 
anti-TRA-1-85, a human-specific cell marker used to 
identify the transplanted cells, and DAPI (4′,6-diamid-
ino-2-phenylindole) staining, which labels both trans-
planted and host nuclei.
Results
Surgical results
Twelve Yucatan minipigs underwent surgical implanta-
tion of the CPCB-RPE1 implant in the subretinal space. 
The surgical technique was shown to be safe and repro-
ducible, with no severe intraoperative complications, 
such as unplanned retinal detachment or iatrogenic reti-
nal tears, significant retinal or choroidal bleeding, nor 
misdelivery of the implant. The lens was spared in all 
surgeries, without inadvertent touch and no opacity were 
noted during or immediately after the procedure.
Imaging of the posterior pole was performed in the 
immediate postoperative period, and, in all cases, 
the implant was clearly visualized in color fundus 
Fig. 7 a Infrared image showing subretinal implant location. b Fluorescein angiography showing blockage of the fluorescein where the implant 
was placed. SD‑OCT observed in c black and white; d colored, the subretinal location of the implant
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photographs as well as IR images, showing successful 
delivery. In FA, the implant was easily identified by fluo-
rescence blockage of the choroid circulation, and SD-
OCT B-scans showed adequate flat positioning of the 
implants in the subretinal space in all subjects, with no 
apparent damage to the retina (Fig. 7).
Histological analysis
HE microscopic analysis demonstrated that all implants 
were unbroken and correctly placed underneath the ret-
ina, associated with only minor damage to the associated 
retinal tissues (Fig. 8).
The hESC-RPE cells that covered the surface of the 
implant were present in a monolayer in all operated eyes, 
as shown by immunohistochemistry (Fig. 9). No TRA-1-
85 + human cells were found underneath the implant or 
within the retina, suggesting that there was no significant 
cell dispersion or migration during the delivery.
Discussion
The rationale behind subretinal transplantation of a 
monolayer of hESC-RPE cells cultured over a scaffold 
prompts the need for the development of a unique sur-
gical technique. Developing a new tissue injector tool to 
improve usability, reproducibility, performance and ulti-
mately surgical safety was essential for the advancement 
of this investigational therapy. Incisions needed to be 
reduced and, therefore, substrate dimensions had to be 
resized in order to fit perfectly inside the cannula without 
overlapping its edges.
These requirements resulted in the design of a smaller 
tissue injector tool, resembling a standard retinal forceps. 
It allowed for the subretinal unfolding and positioning 
of the substrate with a single instrument, making the 
procedure easier, more reliable and reproducible. When 
compared to procedures performed previously with a 
larger tissue injector prototype (unpublished data), sur-
gical time decreased from approximately 90–50  min on 
average, and minor procedure-related complications (e.g. 
small retinal bleeding during retinectomy) seemed to be 
less frequent.
This set of surgeries demonstrated a successful subreti-
nal delivery of the implant without major complications. 
Additionally, the lens and the anterior segment were 
spared from trauma, decreasing the associated inflam-
mation secondary to the lensectomy, which allowed for 
a clear view of the posterior pole during the procedure 
and in the immediate postoperative period. The surgical 
technique showed reproducibility and lack of complica-
tions, essential requirements for moving forward to clini-
cal trials.
This study is limited by the small number of animals, 
and by the lack of long term follow up to access cell sur-
vival and functionality of the implant (e.g. phagocytosis 
of the photoreceptor outer segments by the hESC-RPE) 
[15, 16]. Regarding the newly designed tissue injector, 
although a smaller gauge was achieved, a 17-gauge instru-
ment is still significantly large for eye surgeries. Decreas-
ing the dimensions of the injector, and consequently the 
size of the sclerotomies and retinectomy, might lead to 
an even more controlled procedure. A new generation of 
this tool is under development.
The 17-gauge injector device, however, was shown to 
be useful, easy to handle and safe. It has been designed to 
deliver the CPCB-RPE1 implant in the subretinal space, 
however, this tool may be helpful in other surgical tech-
niques with different kinds of substrates.
Conclusion
In conclusion, the surgical procedure using this innova-
tive device was reproducible and safe in a large animal 
model, causing minimal damage to the transplanted cells 
Fig. 8 HE stained section through an implant removed shortly after 
implantation. Substrate placed in the subretinal space, with minimal 
damage to the retinal layers, photoreceptors intact. Implant thick 
regions shown with arrow; hESC‑RPE on surface of implant shown 
with arrowhead
Fig. 9 Immunohistochemistry analysis: anti‑TRA‑1‑85, a human‑
specific cell marker, was used to identify the transplanted hESC‑RPE 
(arrows)
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as well as to the host tissue. Additional studies in animal 
and human eyes are still necessary to further validate 
these findings.
Abbreviations
hESC‑RPE: human embryonic stem cell‑derived retinal pigment epithelium; 
CPCB‑RPE1: ultrathin Parylene‑C membrane seeded with hESC‑RPE; SD‑OCT: 
spectral domain optical coherence tomography; RPE: retinal pigment epithe‑
lium; AMD: age‑related macular degeneration; FAF: fundus autofluorescence; 
FA: fluorescein angiogram; IR: infrared (images).
Authors’ contributions
Rodrigo A. Brant Fernandes, Francisco R. Stefanini performed procedures, 
analyzed and interpreted data and were major contributors in writing the 
manuscript. Paulo Falabella, Michael J. Koss, Bruno Diniz and Ramiro Ribeiro 
also performed procedures and reviewed analysis, and contributed in writing 
the manuscript. Paulo Schor, Mauricio Maia and Fernando M. Penha worked 
on a thorough and critical review of the manuscript. Trent Wells and Yu‑Chong 
Tai worked on development and improving the injector tool. David R. Hinton 
performed histological analysis and reviewed the manuscript critically. Mark 
Humayun worked on conception and design of the study, as well as on devel‑
opment of the tool. All authors read and approved the final manuscript.
Author details
1 Department of Ophthalmology, USC Roski Eye Institute, Keck School 
of Medicine, University of Southern California, Los Angeles, CA, USA. 2 Depart‑
ment of Ophthalmology and Visual Sciences, Federal University of São 
Paulo, Rua Botucatu, 822, São Paulo, SP 04023‑062, Brazil. 3 Augenzentrum 
Nymphenburger Hoefe, Herzog Carl Theodor Augenklinik, Munich, Germany. 
4 Fundação Universidade Regional de Blumenau, Blumenau, Santa Catarina, 
Brazil. 5 Electrical Engineering, California Institute of Technology, Pasadena, 
CA, USA. 6 Department of Pathology, Keck School of Medicine, University 
of Southern California, Los Angeles, CA, USA. 7 USC Institute for Biomedical 
Therapeutics, Keck School of Medicine, University of Southern California, Los 
Angeles, CA, USA. 
Acknowledgements
Not applicable.
Competing interests
RABF is a patent holder. DRH and MSH are patent holders. DRH and MSH are 
founders and have equity in Regenerative Patch Technologies (RPT) and have 
received grant funding from California Institute of Regenerative Medicine. The 
remaining authors report no relevant financial disclosures.
Availability of data and materials
The data that support the findings of this study are available from the cor‑
responding author upon reasonable request.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was approved by the Animal Care and Use Committee (IACUC) at 
the University of Southern California and also Animal Care and Use Committee 
(CEUA) at the Federal University of Sao Paulo (CEUA N 1710021113).
Funding
Supported by the California Institute of Regenerative Medicine (CIRM), grant 
CIRM DRI‑01444, CIRM CL1‑00521; an unrestricted departmental grant from 
Research to Prevent Blindness, New York, NY 10022; the CAPES Foundation, 
Brasília, Brazil, [BEX 2326‑11‑6 (Brant); BEX 4601‑14‑9 (Falabella)], CNPq (The 
National Council of Research, Brasília, Brazil); the German Research Founda‑
tion DFG Ko4294/1‑1 (Berlin, Germany); the UCSB Institute for Collaborative 
Biotechnologies through grant W911NF‑09‑0001 from the U.S. Army Research 
Office. The content of the information does not necessarily reflect the position 
or the policy of the U.S. Government, and no official endorsement should be 
inferred.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in pub‑
lished maps and institutional affiliations.
Received: 17 July 2017   Accepted: 26 September 2017
References
 1. Sarks SH. Ageing and degeneration in the macular region: a clinico‑
pathological study. Br J Ophthalmol. 1976;60(5):324–41.
 2. Gehrs KM, Anderson DH, Johnson LV, Hageman GS. Age‑related macular 
degeneration—emerging pathogenetic and therapeutic concepts. Ann 
Med. 2006;38(7):450–71.
 3. Michels S, Rosenfeld PJ, Puliafito CA, Marcus EN, Venkatraman AS. 
Systemic bevacizumab (Avastin) therapy for neovascular age‑related 
macular degeneration twelve‑week results of an uncontrolled open‑label 
clinical study. Ophthalmology. 2005;112(6):1035–47.
 4. Ambati J, Ambati BK, Yoo SH, Ianchulev S, Adamis AP. Age‑related macular 
degeneration: etiology, pathogenesis, and therapeutic strategies. Surv 
Ophthalmol. 2003;48(3):257–93.
 5. Evans J. Antioxidant supplements to prevent or slow down the pro‑
gression of AMD: a systematic review and meta‑analysis. Eye (Lond). 
2008;22(6):751–60.
 6. Glenn JV, Mahaffy H, Wu K, et al. Advanced glycation end product (AGE) 
accumulation on Bruch’s membrane: links to age‑related RPE dysfunc‑
tion. Invest Ophthalmol Vis Sci. 2009;50(1):441–51.
 7. Dorey CK, Wu G, Ebenstein D, Garsd A, Weiter JJ. Cell loss in the aging 
retina. Relationship to lipofuscin accumulation and macular degenera‑
tion. Invest Ophthalmol Vis Sci. 1989;30(8):1691–9.
 8. da Cruz L, Chen FK, Ahmado A, Greenwood J, Coffey P. RPE transplanta‑
tion and its role in retinal disease. Prog Retin Eye Res. 2007;26(6):598–635.
 9. Lu B, Zhu D, Hinton D, Humayun MS, Tai YC. Mesh‑supported submicron 
parylene‑C membranes for culturing retinal pigment epithelial cells. 
Biomed Microdevices. 2012;14(4):659–67.
 10. Lee CJ, Vroom JA, Fishman HA, Bent SF. Determination of human lens 
capsule permeability and its feasibility as a replacement for Bruch’s mem‑
brane. Biomaterials. 2006;27(8):1670–8.
 11. Zhu D, Deng X, Spee C, et al. Polarized secretion of PEDF from human 
embryonic stem cell‑derived RPE promotes retinal progenitor cell sur‑
vival. Invest Ophthalmol Vis Sci. 2011;52(3):1573–85.
 12. Montezuma SR, Loewenstein J, Scholz C, Rizzo JF 3rd. Biocompatibility 
of materials implanted into the subretinal space of Yucatan pigs. Invest 
Ophthalmol Vis Sci. 2006;47(8):3514–22.
 13. Koss MJ, Falabella P, Stefanini FR, et al. Subretinal implantation of a 
monolayer of human embryonic stem cell‑derived retinal pigment epi‑
thelium: a feasibility and safety study in Yucatan minipigs. Graefe’s Arch 
Clin Exp Ophthalmol. 2016;254(8):1553–65.
 14. Del Priore LV, Tezel TH, Kaplan HJ. Maculoplasty for age‑related macular 
degeneration: reengineering Bruch’s membrane and the human macula. 
Prog Retin Eye Res. 2006;25(6):539–62.
 15. Hu Y, Liu L, Lu B, et al. A novel approach for subretinal implantation of 
ultrathin substrates containing stem cell‑derived retinal pigment epithe‑
lium monolayer. Ophthalmic Res. 2012;48(4):186–91.
 16. Diniz B, Thomas P, Thomas B, et al. Subretinal implantation of retinal 
pigment epithelial cells derived from human embryonic stem cells: 
improved survival when implanted as a monolayer. Invest Ophthalmol Vis 
Sci. 2013;54(7):5087–96.
